Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Proof-of-concept Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Foralumab in Hospitalized Subjects With Severe COVID-19 and Pulmonary Inflammation

NCT04983446 is registered in ClinicalTrials.gov with Tiziana Life Sciences LTD as lead sponsor.

NCT NCT04983446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04983446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Proof-of-concept Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Foralumab in Hospitalized Subjects With Severe COVID-19 and Pulmonary Inflammation
Lead sponsor
Tiziana Life Sciences LTD
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2022
Completion date
December 30, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 lower respiratory infection, covid-19 respiratory infection, covid19